CN114532982A - System for evaluating complement activation regulation effect of stem cell system transplantation - Google Patents
System for evaluating complement activation regulation effect of stem cell system transplantation Download PDFInfo
- Publication number
- CN114532982A CN114532982A CN202210033255.2A CN202210033255A CN114532982A CN 114532982 A CN114532982 A CN 114532982A CN 202210033255 A CN202210033255 A CN 202210033255A CN 114532982 A CN114532982 A CN 114532982A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- complement activation
- activation
- transplantation
- complement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Prostheses (AREA)
- Materials For Medical Uses (AREA)
Abstract
The invention discloses a system for evaluating the complement activation regulation effect of stem cell system transplantation, which relates to the technical field of stem cell transplantation and comprises the following steps of evaluation object grouping, stage-one complement activation level detection, individual primary treatment, stage-two complement activation level detection, individual secondary treatment, stage-three complement activation level detection, individual tertiary treatment, stage-four complement activation level detection and regulation complement activation effect evaluation. The method comprises the steps of setting evaluation object groups, stage-one complement activation level detection, individual primary treatment, stage-two complement activation level detection, individual secondary treatment, stage-three complement activation level detection, individual tertiary treatment, stage-four complement activation level detection and regulation complement activation effect evaluation, and establishing a standard for measuring the regulation complement activation effect of stem cell system transplantation according to the change of the levels of complement regulatory proteins in different stages.
Description
Technical Field
The invention relates to the technical field of stem cell transplantation, in particular to a system for evaluating the effect of regulating complement activation by stem cell system transplantation.
Background
The stem cell system has a regulating effect on the complement activation of the individual after transplantation. After the complement system is activated, the ordered cascade reaction of the system is carried out, thereby exerting wide biological effect and participating in the defense function of the organism. If the activation of the complement system is out of control, excessive membrane attack complexes may be formed to cause self-damage, or excessive inflammatory mediators may cause pathological effects. Complement activation in the normal body is under tight regulation, thereby maintaining homeostasis in the body. Some of the intermediates generated during complement activation are very unstable and become important self-limiting factors in the complement cascade. In addition, only the antigen-antibody complex formed on the cell surface can trigger the classical pathway, while the C3 convertase of the alternative pathway has stability only on the surface of a specific substance, so that an excessively strong spontaneous complement activation reaction generally cannot occur in a normal organism, and the self-regulation of the complement system plays a role in maintaining the stability of the organism itself. There are a number of soluble membrane-bound complement regulatory factors in the body that interact in specific ways with different complement components, placing complement activation and inhibition in a fine balance, and the absence of regulatory proteins is sometimes responsible for the development of certain diseases. The complement regulatory proteins found at present are more than ten, and can be classified into inhibitors for preventing or limiting the spontaneous activation of complement in liquid phase, regulators for inhibiting or enhancing the normal action of complement on substrates, and inhibitors for protecting body tissues and cells from the destructive action of complement according to their action characteristics. Complement activation is accompanied by changes in the level of complement regulatory protein, which indirectly reflect changes in complement activation. In order to establish a set of standard for measuring the complement activation regulation effect of stem cell system transplantation, a system for evaluating the complement activation regulation effect of stem cell system transplantation is provided.
Disclosure of Invention
Aiming at the defects in the prior art, the invention provides a system for evaluating the complement activation regulation effect of stem cell system transplantation, which is used for establishing a standard for measuring the complement activation regulation effect of stem cell system transplantation.
In order to solve the technical problems, the invention provides the following technical scheme:
the system for evaluating the regulation and control of the complement activation effect of stem cell system transplantation comprises the steps of evaluating object grouping, detecting the level of stage one complement activation, detecting the level of individual primary treatment, detecting the level of stage two complement activation, detecting the level of individual secondary treatment, detecting the level of stage three complement activation, detecting the level of individual tertiary treatment, detecting the level of stage four complement activation and evaluating the regulation and control of the complement activation effect.
The subject groups were evaluated for individual groups divided into A, B two non-transplanted stem cell lines for comparative study evaluation.
Stage one complement activation level assay was used to perform a health level assay on A, B individuals with two non-transplanted stem cell lines.
And (4) treating the individuals once, and performing stem cell system transplantation on A, B individuals of two groups of non-transplanted stem cell systems.
And (3) detecting the level of phase two complement activation, and performing health level detection on A, B two groups of individuals subjected to the primary transplantation stem cell system.
And (4) performing secondary treatment on the individuals subjected to the primary stem cell transplantation system in the group A to perform secondary stem cell transplantation.
And detecting the activation level of the stage three complement, wherein the activation level detection is used for detecting the health level of the group A of individuals transplanted by the secondary stem cell system and tracking and detecting the health level of the group B of individuals transplanted by the primary stem cell system.
And (4) carrying out three times of treatment on the individuals, wherein the group A of individuals subjected to the secondary stem cell transplantation system are subjected to three times of stem cell system transplantation.
And detecting the activation level of the four complements in the stage, wherein the detection is used for detecting the health level of the A group of individuals subjected to the stem cell system transplantation for three times and continuously tracking and detecting the health level of the B group of individuals subjected to the stem cell system transplantation for one time.
And (3) evaluating the effect of regulating complement activation, and obtaining the effect of regulating complement activation by stem cell system transplantation according to the change of the level of complement activation at different stages.
Preferably, the health level test comprises level criteria for units of identification, units of activation and units of membrane attack.
Preferably, the recognition unit includes a recognition unit C1q, a recognition unit C1r, and a recognition unit C1 s.
Preferably, the activation units include activation unit C2, activation unit C3, and activation unit C4.
Preferably, the membrane attack unit comprises a membrane attack unit C5, a membrane attack unit C6, a membrane attack unit C7, a membrane attack unit C8 and a membrane attack unit C9.
Compared with the prior art, the invention has the following beneficial effects:
according to the method, evaluation object groups, stage-one complement activation level detection, individual primary treatment, stage-two complement activation level detection, individual secondary treatment, stage-three complement activation level detection, individual tertiary treatment, stage-four complement activation level detection and regulation complement activation evaluation are set, the detection is performed aiming at the different stages of complement activation levels, the regulation and control action level of the stem cell system transplantation on the complement activation is obtained according to the change of the levels of the complement regulatory proteins at different stages, and therefore the standard for measuring the regulation and control complement activation action of the stem cell system transplantation is established.
Drawings
FIG. 1 is a schematic diagram of the architecture of the present invention for evaluating the regulation of complement activation by stem cell system transplantation;
Detailed Description
The technical solutions in the embodiments of the present invention will be clearly and completely described below with reference to the drawings in the embodiments of the present invention, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all of the embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
As shown in fig. 1, the present invention provides a technical solution: the system for evaluating the regulation and control of the complement activation effect of stem cell system transplantation comprises the steps of evaluating object grouping, detecting the level of stage one complement activation, detecting the level of individual primary treatment, detecting the level of stage two complement activation, detecting the level of individual secondary treatment, detecting the level of stage three complement activation, detecting the level of individual tertiary treatment, detecting the level of stage four complement activation and evaluating the regulation and control of the complement activation effect.
The subject groups were evaluated for individual groups divided into A, B two non-transplanted stem cell lines for comparative study evaluation.
Stage one complement activation level assay for health level testing of A, B individuals with two sets of non-transplanted stem cell systems.
And (4) treating the individuals once, and performing stem cell system transplantation on A, B individuals of two groups of non-transplanted stem cell systems.
And (3) detecting the level of phase two complement activation, and performing health level detection on A, B two groups of individuals subjected to the primary transplantation stem cell system.
And (4) performing secondary treatment on the individuals subjected to the primary stem cell transplantation system in the group A to perform secondary stem cell transplantation.
And detecting the activation level of the stage three complement, wherein the activation level detection is used for detecting the health level of the group A of individuals transplanted by the secondary stem cell system and tracking and detecting the health level of the group B of individuals transplanted by the primary stem cell system.
And (4) carrying out three times of treatment on the individuals, wherein the group A of individuals subjected to the secondary stem cell transplantation system are subjected to three times of stem cell system transplantation.
And detecting the activation level of the four complements in the stage, wherein the activation level detection is used for detecting the health level of the A group of individuals subjected to the stem cell system transplantation for three times and continuously tracking and detecting the health level of the B group of individuals subjected to the stem cell system transplantation for one time.
And (3) evaluating the effect of regulating complement activation, and obtaining the effect of regulating complement activation by stem cell system transplantation according to the change of the level of complement activation at different stages.
As a technical optimization of the invention, the health level test comprises level criteria of identification units, activation units and membrane attack units.
In one technical optimization scheme of the invention, the recognition unit comprises a recognition unit C1q, a recognition unit C1r and a recognition unit C1 s.
As a technical optimization scheme of the invention, the activation units comprise an activation unit C2, an activation unit C3 and an activation unit C4.
As a technical optimization scheme of the invention, the membrane attack unit comprises a membrane attack unit C5, a membrane attack unit C6, a membrane attack unit C7, a membrane attack unit C8 and a membrane attack unit C9.
In conclusion, the invention sets evaluation object groups, stage-one complement activation level detection, individual primary treatment, stage-two complement activation level detection, individual secondary treatment, stage-three complement activation level detection, individual tertiary treatment, stage-four complement activation level detection and regulation complement activation evaluation, detects the different stages of complement activation levels, and obtains the regulation and control action level of the stem cell system transplantation on the complement activation according to the change of the levels of the complement regulatory proteins at different stages, thereby establishing the standard for measuring the regulation and control complement activation action of the stem cell system transplantation.
It is noted that, herein, relational terms such as first and second, and the like may be used solely to distinguish one entity or action from another entity or action without necessarily requiring or implying any actual such relationship or order between such entities or actions. Also, the terms "comprises," "comprising," or any other variation thereof, are intended to cover a non-exclusive inclusion, such that a process, method, article, or apparatus that comprises a list of elements does not include only those elements but may include other elements not expressly listed or inherent to such process, method, article, or apparatus.
Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that changes, modifications, substitutions and alterations can be made in these embodiments without departing from the principles and spirit of the invention, the scope of which is defined in the appended claims and their equivalents.
Claims (5)
1. The system for evaluating the regulation and control of complement activation by stem cell system transplantation is characterized in that: the method comprises the following steps of grouping evaluation objects, detecting the activation level of a first stage complement, detecting the activation level of a second stage complement, detecting the activation level of a third stage complement, treating the third stage complement, detecting the activation level of a fourth stage complement and evaluating the activation effect of a regulation complement;
the evaluation object group is used for dividing A, B individual groups of two non-transplanted stem cell systems for research comparative evaluation;
stage one complement activation level detection for health level detection of A, B individuals with two sets of non-transplanted stem cell systems;
the individual primary treatment is used for carrying out stem cell system transplantation on A, B individuals of two groups of non-transplanted stem cell systems;
stage two complement activation level detection, used for carrying out health level detection on A, B two groups of individuals subjected to primary transplantation stem cell system;
performing secondary treatment on the individuals subjected to the primary stem cell transplantation system in the group A, and performing secondary stem cell transplantation on the individuals subjected to the primary stem cell transplantation system in the group A;
stage three complement activation level detection, which is used for carrying out health level detection on the A group of individuals subjected to the secondary stem cell system transplantation and carrying out health level tracking detection on the B group of individuals subjected to the primary stem cell system transplantation;
carrying out three times of treatment on the individuals, wherein the individuals are subjected to the secondary stem cell transplantation of the group A;
stage four complement activation level detection, which is used for carrying out health level detection on the A group of individuals subjected to the three stem cell system transplants and carrying out health level tracking detection on the B group of individuals subjected to the one stem cell system transplantation;
and (3) evaluating the effect of regulating complement activation, and obtaining the effect of regulating complement activation by stem cell system transplantation according to the change of the level of complement activation at different stages.
2. The system for assessing regulation of complement activation by stem cell system transplantation according to claim 1, wherein: the health level test includes level criteria for identification units, activation units, and membrane attack units.
3. The system for assessing regulation of complement activation by stem cell system transplantation according to claim 2, wherein: the recognition unit includes a recognition unit C1q, a recognition unit C1r, and a recognition unit C1 s.
4. The system for assessing regulation of complement activation by stem cell system transplantation according to claim 2, wherein: the activation units include activation unit C2, activation unit C3, and activation unit C4.
5. The system for assessing regulation of complement activation by stem cell system transplantation according to claim 2, wherein: the film attack units comprise a film attack unit C5, a film attack unit C6, a film attack unit C7, a film attack unit C8 and a film attack unit C9.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210033255.2A CN114532982A (en) | 2022-01-12 | 2022-01-12 | System for evaluating complement activation regulation effect of stem cell system transplantation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210033255.2A CN114532982A (en) | 2022-01-12 | 2022-01-12 | System for evaluating complement activation regulation effect of stem cell system transplantation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114532982A true CN114532982A (en) | 2022-05-27 |
Family
ID=81671326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210033255.2A Pending CN114532982A (en) | 2022-01-12 | 2022-01-12 | System for evaluating complement activation regulation effect of stem cell system transplantation |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114532982A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486745A (en) * | 2003-06-17 | 2004-04-07 | 中国医学科学院血液学研究所 | Stem cell prepn for treating tissue ischemia disease and its prepn process |
| AU2005244012A1 (en) * | 2004-05-14 | 2005-11-24 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| CN101437501A (en) * | 2006-03-02 | 2009-05-20 | 阿莱克申药物公司 | Prolongation of survival of an allograft by inhibiting complement activity |
| WO2018075462A1 (en) * | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating and preventing transplant-associated injury |
| CN111278449A (en) * | 2017-08-15 | 2020-06-12 | 奥默罗斯公司 | Method for the treatment and/or prevention of graft versus host disease and/or diffuse alveolar hemorrhage and/or venous occlusive disease associated with hematopoietic stem cell transplantation |
-
2022
- 2022-01-12 CN CN202210033255.2A patent/CN114532982A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1486745A (en) * | 2003-06-17 | 2004-04-07 | 中国医学科学院血液学研究所 | Stem cell prepn for treating tissue ischemia disease and its prepn process |
| AU2005244012A1 (en) * | 2004-05-14 | 2005-11-24 | Alexion Pharmaceuticals, Inc. | Prolongation of survival of an allograft by inhibiting complement activity |
| CN101437501A (en) * | 2006-03-02 | 2009-05-20 | 阿莱克申药物公司 | Prolongation of survival of an allograft by inhibiting complement activity |
| WO2018075462A1 (en) * | 2016-10-17 | 2018-04-26 | Medical University Of South Carolina | Compositions and methods for treating and preventing transplant-associated injury |
| CN111278449A (en) * | 2017-08-15 | 2020-06-12 | 奥默罗斯公司 | Method for the treatment and/or prevention of graft versus host disease and/or diffuse alveolar hemorrhage and/or venous occlusive disease associated with hematopoietic stem cell transplantation |
Non-Patent Citations (2)
| Title |
|---|
| 陶章: "胚胎干细胞多次移植对博莱霉素致小鼠肺损伤的治疗作用", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》, pages 25 - 50 * |
| 高谋；徐如祥；王文佳；董勤； 丁柏匀；姚慧；杨志军: "诱导型神经干细胞移植抑制颅脑创伤后补体活化的影响", 《中华神经创伤外科电子杂志》, pages 2 - 7 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Patel et al. | Molecular taxonomy of human ocular outflow tissues defined by single-cell transcriptomics | |
| Schneider et al. | NADPH oxidase and extracellular regulated kinases 1/2 are targets of prion protein signaling in neuronal and nonneuronal cells | |
| Nielsen et al. | Identification of differentially expressed genes in keratoconus epithelium analyzed on microarrays | |
| An et al. | Impaired neurogenesis and cardiovascular development in mice lacking the E3 ubiquitin ligases UBR1 and UBR2 of the N-end rule pathway | |
| CN109872777A (en) | The screening technique of Hibiscus hamabo real-time fluorescence quantitative PCR reference gene | |
| Clark et al. | Protein complex stoichiometry and expression dynamics of transcription factors modulate stem cell division | |
| Yu et al. | Root type-specific reprogramming of maize pericycle transcriptomes by local high nitrate results in disparate lateral root branching patterns | |
| Carmona et al. | Automated identification of reference genes based on RNA-seq data | |
| Aguila et al. | Spatial RNA sequencing identifies robust markers of vulnerable and resistant human midbrain dopamine neurons and their expression in Parkinson’s disease | |
| CN115136242A (en) | Accurate and robust information deconvolution from a large number of tissue transcriptomes | |
| Lensink et al. | Outreach and efficiency of microfinance institutions: Is there a trade-off | |
| Pathak et al. | The effect of culture medium and carrier on explant culture of human limbal epithelium: A comparison of ultrastructure, keratin profile and gene expression | |
| CN114532982A (en) | System for evaluating complement activation regulation effect of stem cell system transplantation | |
| Lupasco et al. | Corneal epithelium in keratoconus underexpresses active NRF2 and a subset of oxidative stress-related genes | |
| Chu et al. | RNA network interactions during differentiation of human trophoblasts | |
| Kalish et al. | Temporal genomics of vein bypass grafting through oligonucleotide microarray analysis | |
| Chiou et al. | Genomic signatures of extreme body size divergence in baboons | |
| Zhang et al. | Global analysis of canola genes targeted by SHORT HYPOCOTYL UNDER BLUE 1 during endosperm and embryo development | |
| Ikkala et al. | Unilateral corneal insult in Zebrafish results in a bilateral cell shape and identity modification, supporting wound closure | |
| Boyd et al. | Monetary regimes and inflation in 12 Caribbean economies | |
| CN113998746B (en) | Intelligent control method and system of water purifier, electronic equipment and storage medium | |
| Franchini et al. | The ALOG family members OsG1L1 and OsG1L2 regulate inflorescence branching in rice | |
| LU502780B1 (en) | Methods for stratification of parkinson's disease patients, systems and uses thereof | |
| Sun | Genomic Studies of Gene Expression Errors and Their Evolutionary Ramifications | |
| Choobineh et al. | A nonparametric small sample estimator of mean residual life |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |